ONCY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Oncolytics Biotech Inc (ONCY) is not a strong buy at this moment for a beginner investor with a long-term perspective. The lack of significant positive catalysts, weak financial performance, and neutral trading sentiment suggest that the stock does not present an immediate opportunity. While the stock has potential for long-term growth, the current technical indicators and analyst revisions do not strongly support an entry at this time.
The MACD is positive and contracting, RSI is neutral at 54.341, and moving averages are converging. The stock is trading near the pivot level of 1.06, with resistance at 1.161 and support at 0.959. No strong technical signals indicate a clear buy opportunity.
The company is aligning with the FDA on a pivotal study for pelareorep in squamous cell anal carcinoma, which could be a long-term growth driver.
No recent news or significant trading trends. Analyst Chad Messer lowered the price target from $7 to $5, reflecting tempered expectations.
In Q4 2025, revenue remained at $0 with no growth, net income improved by 53.73% YoY but remains negative at -$12.4M, and EPS increased by 40% YoY to -0.14. The company is still unprofitable.
Lake Street analyst Chad Messer maintains a Buy rating but lowered the price target from $7 to $5, reflecting cautious optimism.
